UOC
MIRM icon

UBS O'Connor’s Mirum Pharmaceuticals MIRM Stock Holding History

UBS O'Connor’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$11.3K – 567
2024
Q2 		$11.3K Sell
10,000
-15,000
-60% -$393K ﹤0.01% 499
2024
Q1 		$26.9K Buy
+25,000
New +$687K ﹤0.01% 457

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

UBS O'Connor's MIRM Position: Q3 2025 in Review

UBS O'Connor sold out of Mirum Pharmaceuticals (MIRM) in Q3 2025, closing a stake of 21,409 shares — an estimated $1.09M sold.

UBS O'Connor first reported a position in MIRM in Q2 2023 and held it in 9 quarters. The position peaked at $1.93M in Q3 2023. 272 funds tracked by Wall St. Rank hold MIRM as of Q3 2025.

  • UBS O'Connor reported no remaining Mirum Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 21,409 Mirum Pharmaceuticals shares in Q3 2025, an estimated $1.09M.
  • UBS O'Connor first reported a position in Mirum Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • UBS O'Connor's Mirum Pharmaceuticals position peaked at $1.93M in Q3 2023.
  • 272 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.